- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 612369, 10 pages
Mitochondria and Cancer: Past, Present, and Future
1Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON, Canada L8V 5C2
2Department of Pathology and Molecular Medicine, McMaster University, 1280 Main Street W, Hamilton, ON, Canada L8N 3Z5
3Mitomics Inc., Bioincubator Suite, The Medical School, New Castle University, Framlington Place, Newcastle Upon Tyne NE2 4HH, UK
4Cipher Systems, Annapolis, MD 21401, USA
5Mitomics Inc., 290 Munro Street, Suite 1000, Thunder Bay, ON, Canada P7A 7T1
Received 30 October 2012; Accepted 13 December 2012
Academic Editor: George Perry
Copyright © 2013 M. L. Verschoor et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. L. Lehninger, The Mitochondrion- Molecular Basis of Structure and Function, 1965.
- L. Ernster and G. Schatz, “Mitochondria: a historical review,” Journal of Cell Biology, vol. 91, no. 3, part 2, pp. 227s–255s, 1981.
- P. Siekevitz, “Powerhouse of the cell,” Scientific American, no. 1, pp. 131–140, 1957.
- P. P. Slonimski and B. Ephrussi, “Action de l'acriflavine sur les levures. V. Le systeme des cytochromes des mutants ‘petite colonie’,” Annales de l'Institut Pasteur, vol. 77, pp. 47–63, 1949.
- M. M. Nass and S. Nass, “Intramitochondrial fibers with DNA characteristics. I. Fixation and electron staining reactions,” Journal of Cell Biology, vol. 19, pp. 593–629, 1963.
- G. Schatz and J. Klima, “Triphosphopyridine nucleotide: cytochrome C reductase of Saccharomyces Cerevisiae a ‘microsomal’ enzyme,” Biochimica et Biophysica Acta, vol. 81, no. 3, pp. 448–461, 1964.
- S. Anderson, A. T. Bankier, B. G. Barrell, et al., “Sequence and organization of the human mitochondrial genome,” Nature, vol. 290, no. 5806, pp. 457–465, 1981.
- R. M. Andrews, I. Kubacka, P. F. Chinnery, R. N. Lightowlers, D. M. Turnbull, and N. Howell, “Reanalysis and revision of the cambridge reference sequence for human mitochondrial DNA,” Nature Genetics, vol. 23, no. 2, p. 147, 1999.
- D. C. Wallace, G. Singh, M. T. Lott et al., “Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy,” Science, vol. 242, no. 4884, pp. 1427–1430, 1988.
- I. J. Holt, A. E. Harding, and J. A. Morgan-Hughes, “Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies,” Nature, vol. 331, no. 6158, pp. 717–719, 1988.
- L. C. Greaves, A. K. Reeve, R. W. Taylor, and D. M. Turnbull, “Mitochondrial DNA and disease,” The Journal of Pathology, vol. 226, no. 2, pp. 274–286, 2012.
- S. E. Durham, K. J. Krishnan, J. Betts, and M. A. Birch-Machin, “Mitochondrial DNA damage in non-melanoma skin cancer,” British Journal of Cancer, vol. 88, no. 1, pp. 90–95, 2003.
- O. Warburg, K. Posener, and E. Negelein, “Ueber den Stoffwechsel der Tumoren,” Biochemische Zeitschrift, vol. 152, pp. 319–344, 1924.
- O. Warburg, “On the origin of cancer cells,” Science, vol. 123, no. 3191, pp. 309–314, 1956.
- J. C. Thrash, A. Boyd, M. J. Huggett, et al., “Phylogenomic evidence for a common ancestor of mitochondria and the SAR11 clade,” Scientific Reports, vol. 1, article 13, 2011.
- Y. Chen, R. Cairns, I. Papandreou, A. Koong, and N. C. Denko, “Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect,” PLoS One, vol. 4, no. 9, Article ID e7033, 2009.
- F. Weinberg, R. Hamanaka, W. W. Wheaton et al., “Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 19, pp. 8788–8793, 2010.
- D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
- S. S. Gambhir, “Molecular imaging of cancer with positron emission tomography,” Nature Reviews Cancer, vol. 2, no. 9, pp. 683–693, 2002.
- P. S. Ward and C. B. Thompson, “Metabolic reprogramming: a cancer hallmark even warburg did not anticipate,” Cancer Cell, vol. 21, no. 3, pp. 297–308, 2012.
- G. Kroemer and J. Pouyssegur, “Tumor cell metabolism: cancer's Achilles' heel,” Cancer Cell, vol. 13, no. 6, pp. 472–482, 2008.
- J. Pouysségur, F. Dayan, and N. M. Mazure, “Hypoxia signalling in cancer and approaches to enforce tumour regression,” Nature, vol. 441, no. 7092, pp. 437–443, 2006.
- P. Swietach, R. D. Vaughan-Jones, and A. L. Harris, “Regulation of tumor pH and the role of carbonic anhydrase 9,” Cancer and Metastasis Reviews, vol. 26, no. 2, pp. 299–310, 2007.
- K. Fischer, P. Hoffmann, S. Voelkl et al., “Inhibitory effect of tumor cell-derived lactic acid on human T cells,” Blood, vol. 109, no. 9, pp. 3812–3819, 2007.
- M. I. Koukourakis, A. Giatromanolaki, A. L. Harris, and E. Sivridis, “Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma,” Cancer Research, vol. 66, no. 2, pp. 632–637, 2006.
- R. A. Zager, A. C. M. Johnson, S. Y. Hanson, and S. Lund, “Acute nephrotoxic and obstructive injury primes the kidney to endotoxin-driven cytokine/chemokine production,” Kidney International, vol. 69, no. 7, pp. 1181–1188, 2006.
- M. L. Verschoor, L. A. Wilson, and G. Singh, “Mechanisms associated with mitochondrialgenerated reactive oxygen species in cancer,” Canadian Journal of Physiology and Pharmacology, vol. 88, no. 3, pp. 204–219, 2010.
- T. Cheng, J. Sudderth, C. Yang et al., “Pyruvate carboxylase is required for glutamine-independent growth of tumor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 21, pp. 8674–8679, 2011.
- R. J. Deberardinis and T. Cheng, “Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer,” Oncogene, vol. 29, no. 3, pp. 313–324, 2010.
- J. Y. Kim, Y. Kanai, A. Chairoungdua et al., “Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells,” Biochimica et Biophysica Acta, vol. 1512, no. 2, pp. 335–344, 2001.
- W. J. Chung, S. A. Lyons, G. M. Nelson et al., “Inhibition of cystine uptake disrupts the growth of primary brain tumors,” Journal of Neuroscience, vol. 25, no. 31, pp. 7101–7110, 2005.
- Y. Huang, Z. Dai, C. Barbacioru, and W. Sadée, “Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance,” Cancer Research, vol. 65, no. 16, pp. 7446–7454, 2005.
- J. de Groot and H. Sontheimer, “Glutamate and the biology of gliomas,” GLIA, vol. 59, no. 8, pp. 1181–1189, 2011.
- E. P. Seidlitz, M. K. Sharma, and G. Singh, “A by-product of glutathione production in cancer cells may cause disruption in bone metabolic processes,” Canadian Journal of Physiology and Pharmacology, vol. 88, no. 3, pp. 197–203, 2010.
- A. Chatterjee, S. Dasgupta, and D. Sidransky, “Mitochondrial subversion in cancer,” Cancer Prevention Research, vol. 4, no. 5, pp. 638–654, 2011.
- H. A. Coller, K. Khrapko, N. D. Bodyak, E. Nekhaeva, P. Herrero-Jimenez, and W. G. Thilly, “High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection,” Nature Genetics, vol. 28, no. 2, pp. 147–150, 2001.
- M. Sanchez-Cespedes, P. Parrella, S. Nomoto et al., “Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors,” Cancer Research, vol. 61, no. 19, pp. 7015–7019, 2001.
- A. Lièvre, C. Chapusot, A. M. Bouvier et al., “Clinical value of mitochondrial mutations in colorectal cancer,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3517–3525, 2005.
- K. K. Singh and M. Kulawiec, “Mitochondrial DNA polymorphism and risk of cancer,” Methods in Molecular Biology, vol. 471, pp. 291–303, 2009.
- L. M. Booker, G. M. Habermacher, B. C. Jessie et al., “North American white mitochondrial haplogroups in prostate and renal cancer,” Journal of Urology, vol. 175, no. 2, pp. 468–472, 2006.
- M. Kulawiec, K. M. Owens, and K. K. Singh, “MtDNA G10398A variant in African-American women with breast cancer provides resistance to apoptosis and promotes metastasis in mice,” Journal of Human Genetics, vol. 54, no. 11, pp. 647–654, 2009.
- V. W. Setiawan, L. H. Chu, E. M. John et al., “Mitochondrial DNA G10398A variant is not associated with breast cancer in African-American women,” Cancer Genetics and Cytogenetics, vol. 181, no. 1, pp. 16–19, 2008.
- K. Darvishi, S. Sharma, A. K. Bhat, E. Rai, and R. N. K. Bamezai, “Mitochondrial DNA G10398A polymorphism imparts maternal Haplogroup N a risk for breast and esophageal cancer,” Cancer Letters, vol. 249, no. 2, pp. 249–255, 2007.
- M. P. Mims, T. G. Hayes, S. Zheng et al., “Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women,” Cancer Research, vol. 66, no. 3, pp. 1880–1881, 2006.
- J. A. Canter, A. R. Kallianpur, F. F. Parl, and R. C. Millikan, “Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women,” Cancer Research, vol. 65, no. 17, pp. 8028–8033, 2005.
- R. K. Bai, S. M. Leal, D. Covarrubias, A. Liu, and L. J. C. Wong, “Mitochondrial genetic background modifies breast cancer risk,” Cancer Research, vol. 67, no. 10, pp. 4687–4694, 2007.
- E. T. Lam, P. M. Bracci, E. A. Holly, et al., “Mitochondrial DNA sequence variation and risk of pancreatic cancer,” Cancer Research, vol. 72, no. 3, pp. 686–695, 2012.
- C. J. Turner, C. Granycome, R. Hurst et al., “Systematic segregation to mutant mitochondrial DNA and accompanying loss of mitochondrial DNA in human NT2 teratocarcinoma cybrids,” Genetics, vol. 170, no. 4, pp. 1879–1885, 2005.
- A. K. Rasmussen, A. Chatterjee, L. J. Rasmussen, and K. K. Singh, “Mitochondria-mediated nuclear mutator phenotype in Saccharomyces cerevisiae,” Nucleic Acids Research, vol. 31, no. 14, pp. 3909–3917, 2003.
- G. Amuthan, G. Biswas, S. Y. Zhang, A. Klein-Szanto, C. Vijayasarathy, and N. G. Avadhani, “Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion,” EMBO Journal, vol. 20, no. 8, pp. 1910–1920, 2001.
- M. Higuchi, T. Kudo, S. Suzuki et al., “Mitochondrial DNA determines androgen dependence in prostate cancer cell lines,” Oncogene, vol. 25, no. 10, pp. 1437–1445, 2006.
- J. Maki, K. Robinson, B. Reguly et al., “Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens,” American Journal of Clinical Pathology, vol. 129, no. 1, pp. 57–66, 2008.
- K. Robinson, J. Creed, B. Reguly et al., “Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay,” Prostate Cancer and Prostatic Diseases, vol. 13, no. 2, pp. 126–131, 2010.
- K. Polyak, Y. Li, H. Zhu et al., “Somatic mutations of the mitochondrial genome in human colorectal tumours,” Nature Genetics, vol. 20, no. 3, pp. 291–293, 1998.
- M. S. Fliss, H. Usadel, O. L. Caballero et al., “Facile detection of mitochondrial DNA mutations in tumors and bodily fluids,” Science, vol. 287, no. 5460, pp. 2017–2019, 2000.
- J. P. Jakupciak, S. Maragh, M. E. Markowitz et al., “Performance of mitochondrial DNA mutations detecting early stage cancer,” BMC Cancer, vol. 8, article 285, 2008.
- P. M. Vallone, J. P. Jakupciak, and M. D. Coble, “Forensic application of the affymetrix human mitochondrial resequencing array,” Forensic Science International, vol. 1, no. 2, pp. 196–198, 2007.
- E. Zietkiewicz, M. Witt, P. Daca, J. Zebracka-Gala, M. Goniewicz, and B. Jarzab, “Current genetic methodologies in the identification of disaster victims and in forensic analysis,” Journal of Applied Genetics, vol. 53, no. 1, pp. 41–60, 2012.
- B. Reguly, J. P. Jakupciak, and R. L. Parr, “3.4 kb mitochondrial genome deletion serves as a surrogate predictive biomarker for prostate cancer in histopathologically benign biopsy cores,” Journal of the Canadian Urological Association, vol. 4, no. 5, pp. E118–E122, 2010.
- S. Ebner, R. Lang, E. E. Mueller, et al., “Mitochondrial haplogroups, control region polymorphisms and malignant melanoma: a study in middle European Caucasians,” PLoS One, vol. 6, no. 12, Article ID e27192, 2011.
- R. L. Parr, J. Maki, B. Reguly et al., “The pseudo-mitochondrial genome influences mistakes in heteroplasmy interpretation,” BMC Genomics, vol. 7, article 185, 2006.
- J. P. Jakupciak, G. D. Dakubo, S. Maragh, and R. L. Parr, “Analysis of potential cancer biomarkers in mitochondrial DNA,” Current Opinion in Molecular Therapeutics, vol. 8, no. 6, pp. 500–506, 2006.
- W. H. Koppenol, P. L. Bounds, and C. V. Dang, “Otto Warburg's contributions to current concepts of cancer metabolism,” Nature Reviews Cancer, vol. 11, no. 5, pp. 325–337, 2011.
- A. Mayevsky and G. G. Rogatsky, “Mitochondrial function in vivo evaluated by NADH fluorescence: from animal models to human studies,” American Journal of Physiology, vol. 292, no. 2, pp. C615–C640, 2007.
- A. Mayevsky, R. Walden, E. Pewzner, et al., “Mitochondrial function and tissue vitality: bench-to-bedside real-time optical monitoring system,” Journal of Biomedical Optics, vol. 16, no. 6, Article ID 067004, 2011.
- P. Bottoni, B. Giardina, A. Pontoglio, S. Scara, and R. Scatena, “Mitochondrial proteomic approaches for new potential diagnostic and prognostic biomarkers in cancer,” Advances in Experimental Medicine and Biology, vol. 942, pp. 423–440, 2012.
- R. Reja, A. J. Venkatakrishnan, J. Lee et al., “MitoInteractome: mitochondrial protein interactome database, and its application in ‘aging network’ analysis,” BMC Genomics, vol. 10, supplement 3, p. S20, 2009.
- M. Elstner, C. Andreoli, T. Klopstock, T. Meitinger, and H. Prokisch, “The mitochondrial proteome database: MitoP2,” Methods in Enzymology, vol. 457, pp. 3–20, 2009.
- A. C. Smith, J. A. Blackshaw, and A. J. Robinson, “MitoMiner: a data warehouse for mitochondrial proteomics data,” Nucleic Acids Research, vol. 40, pp. 1160–1167, 2012.
- R. Scatena, “Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation,” Advances in Experimental Medicine and Biology, vol. 942, pp. 287–308, 2012.
- Y. W. Chen, H. C. Chou, P. C. Lyu et al., “Mitochondrial proteomics analysis of tumorigenic and metastatic breast cancer markers,” Functional and Integrative Genomics, vol. 11, no. 2, pp. 225–239, 2011.
- R. Wadhwa, T. Yaguchi, M. K. Hasan, Y. Mitsui, R. R. Reddel, and S. C. Kaul, “Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein,” Experimental Cell Research, vol. 274, no. 2, pp. 246–253, 2002.
- R. Wadhwa, T. Yaguchi, M. K. Hasan, K. Taira, and S. C. Kaul, “Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation,” Biochemical and Biophysical Research Communications, vol. 302, no. 4, pp. 735–742, 2003.
- A. Maitra, Y. Cohen, S. E. D. Gillespie et al., “The human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection,” Genome Research, vol. 14, no. 5, pp. 812–819, 2004.
- J. C. Castle, M. Biery, H. Bouzek et al., “DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing,” BMC Genomics, vol. 11, no. 1, article 244, 2010.
- L. Fendt, H. Niederstätter, G. Huber et al., “Accumulation of mutations over the entire mitochondrial genome of breast cancer cells obtained by tissue microdissection,” Breast Cancer Research and Treatment, vol. 128, no. 2, pp. 327–336, 2011.
- H. D. Hosgood III, C. S. Liu, N. Rothman et al., “Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study,” Carcinogenesis, vol. 31, no. 5, pp. 847–849, 2010.
- S. Nomoto, K. Yamashita, K. Koshikawa, A. Nakao, and D. Sidransky, “Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma,” Clinical Cancer Research, vol. 8, no. 2, pp. 481–487, 2002.
- S. Dasgupta, R. Koch, W. H. Westra et al., “Mitochondrial DNA mutation in normal margins and tumors of recurrent head and neck squamous cell carcinoma patients,” Cancer Prevention Research, vol. 3, no. 9, pp. 1205–1211, 2010.
- Y. Jiang and X. Wang, “Comparative mitochondrial proteomics: perspective in human diseases,” Journal of Hematology & Oncology, vol. 5, article 11, 2012.
- G. D. Dakubo, J. P. Jakupciak, M. A. Birch-Machin, and R. L. Parr, “Clinical implications and utility of field cancerization,” Cancer Cell International, vol. 7, article 2, 2007.
- R. L. Parr, G. D. Dakubo, K. A. Crandall et al., “Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology,” Journal of Molecular Diagnostics, vol. 8, no. 3, pp. 312–319, 2006.
- K. A. Trujillo, A. C. Jones, J. K. Griffith, and M. Bisoffi, “Markers of field cancerization: proposed clinical applications in prostate biopsies,” Prostate Cancer, vol. 2012, Article ID 302894, 2012.
- J. A. O'Shaughnessy, G. J. Kelloff, G. B. Gordon et al., “Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development: recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia,” Clinical Cancer Research, vol. 8, no. 2, pp. 314–346, 2002.
- J. P. Jakupciak, A. Maggrah, S. Maragh et al., “Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0,” BMC Cancer, vol. 8, article 95, 2008.
- S. Dasgupta, C. Shao, T. E. Keane, et al., “Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients,” International Journal of Cancer, vol. 131, no. 1, pp. 158–164, 2012.
- J. Ellinger, D. C. Muller, S. C. Muller, et al., “Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies,” Urologic Oncology, vol. 30, no. 4, pp. 509–515, 2012.
- J. Ellinger, S. C. Müller, N. Wernert, A. von Ruecker, and P. J. Bastian, “Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy,” British Journal of Urology International, vol. 102, no. 5, pp. 628–632, 2008.
- J. Traba, A. Del Arco, M. R. Duchen, G. Szabadkai, and J. Satrustegui, “SCaMC-1 promotes cancer cell survival by desensitizing mitochondrial permeability transition via ATP/ADP-mediated matrix Ca(2+) buffering,” Cell Death & Differentiation, vol. 19, no. 4, pp. 650–660, 2012.
- O. Catalina-Rodriguez, V. K. Kolukula, Y. Tomita, et al., “The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis,” Oncotarget, vol. 3, no. 10, pp. 1220–1235, 2012.
- F. Balloux, L. J. Handley, T. Jombart, H. Liu, and A. Manica, “Climate shaped the worldwide distribution of human mitochondrial DNA sequence variation,” Proceedings of the Royal Society B, vol. 276, no. 1672, pp. 3447–3455, 2009.
- A. Naito, J. Carcel-Trullols, C. H. Xie, T. T. Evans, T. Mizumachi, and M. Higuchi, “Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line,” International Journal of Cancer, vol. 122, no. 7, pp. 1506–1511, 2008.
- J. A. Dykens, L. D. Marroquin, and Y. Will, “Strategies to reduce late-stage drug attrition due to mitochondrial toxicity,” Expert Review of Molecular Diagnostics, vol. 7, no. 2, pp. 161–175, 2007.